摘要
目的探讨度伐利尤单抗联合依托泊苷胶囊治疗复发广泛期小细胞肺癌疗效。方法选取2021年1月至2022年12月宜春市人民医院收治的40例复发广泛期小细胞肺癌患者作为研究对象,采用随机数字表法将其分为对照组和观察组,各20例。对照组患者采用依托泊苷胶囊治疗,观察组患者采用度伐利尤单抗联合依托泊苷胶囊治疗。比较两组患者的临床疗效、化疗前后血清神经元特异性烯醇化酶(NSE)水平变化、治疗期间的不良反应以及远期生存情况的差异。结果观察组的客观有效率、疾病控制率均高于对照组,差异有统计学意义(P<0.05);观察组化疗后的血清NSE水平低于对照组,差异有统计学意义(P<0.05);两组治疗期间白细胞减少、血小板减少、中性粒细胞减少、胃肠道反应、肝肾损害等不良反应的发生率及严重程度比较,差异无统计学意义(P>0.05);观察组无进展生存期、总生存期均长于对照组,差异有统计学意义(P<0.05)。结论度伐利尤单抗联合依托泊苷胶囊治疗复发广泛期小细胞肺癌疗效较单独使用依托泊苷胶囊显著提升,能够明显延长患者的生存时间,且不会明显增加不良反应,值得临床推荐。
Objective To investigate the efficacy of Duvalizumab combined with Etoposide Capsules in the treatment of recurrent extensive small cell lung cancer.Methods A total of forty patients with recurrent extensive small cell lung cancer admitted to Yichun People's Hospital from January 2021 to December 2022 were selected as the study subjects.They were divided into control group and observation group by random number table method,with 20 cases in each group.The control group patients were treated with Etoposide Capsules,while the observation group patients were treated with Duvalizumab combined with Etoposide Capsules.The clinical efficacy,changes in serum neuron-specific enolase(NSE)levels before and after chemotherapy,adverse reactions during treatment and long-term survival were compared between the two groups.Results The objective response rate and disease control rate of the observation group were higher than those of the control group,with statistically significant differences(P<0.05).The serum NSE level in the observation group after chemotherapy was lower than that in the control group,with statistically significant difference(P<0.05).There were no statistically significant differences in the incidence and severity of adverse reactions such as leukopenia,thrombocytopenia,neutropenia,gastrointestinal reactions,liver and kidney damage between the two groups during the treatment period(P>0.05).The observation group had longer progression free survival and overall survival compared to the control group,with statistically significant difference(P<0.05).Conclusion The combination of Duvalizumab and Etoposide Capsules has a significantly improved therapeutic effect on recurrent extensive small cell lung cancer compared to the use of Etoposide Capsules alone.It can significantly prolong the survival time of patients without significantly increasing adverse reactions,and is worthy of clinical recommendation.
作者
彭黎明
PENG Liming(Department of Oncology,Yichun People's Hospital,Jiangxi Province,Yichun 336000,China)
出处
《中国当代医药》
CAS
2024年第15期48-51,共4页
China Modern Medicine
基金
江西省卫生健康委科技计划项目(202212688)。
